These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 29229605)

  • 41. Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells.
    Mologni L; Costanza M; Sharma GG; Viltadi M; Massimino L; Citterio S; Purgante S; Raman H; Pirola A; Zucchetti M; Piazza R; Gambacorti-Passerini C
    Neoplasia; 2018 May; 20(5):467-477. PubMed ID: 29605720
    [TBL] [Abstract][Full Text] [Related]  

  • 42. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.
    Miao B; Ji Z; Tan L; Taylor M; Zhang J; Choi HG; Frederick DT; Kumar R; Wargo JA; Flaherty KT; Gray NS; Tsao H
    Cancer Discov; 2015 Mar; 5(3):274-87. PubMed ID: 25542448
    [TBL] [Abstract][Full Text] [Related]  

  • 43. miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment.
    Liu S; Tetzlaff MT; Wang T; Yang R; Xie L; Zhang G; Krepler C; Xiao M; Beqiri M; Xu W; Karakousis G; Schuchter L; Amaravadi RK; Xu W; Wei Z; Herlyn M; Yao Y; Zhang L; Wang Y; Zhang L; Xu X
    Pigment Cell Melanoma Res; 2015 Jul; 28(4):431-41. PubMed ID: 25903073
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma.
    Guerreschi P; Scalbert C; Qassemyar A; Kluza J; Ravasi L; Huglo D; Martinot-Duquennoy V; Formstecher P; Marchetti P; Mortier L
    Melanoma Res; 2013 Oct; 23(5):373-80. PubMed ID: 23852164
    [TBL] [Abstract][Full Text] [Related]  

  • 45. miR-524-5p suppresses the growth of oncogenic BRAF melanoma by targeting BRAF and ERK2.
    Liu SM; Lu J; Lee HC; Chung FH; Ma N
    Oncotarget; 2014 Oct; 5(19):9444-59. PubMed ID: 25275294
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of VEGFR-1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib.
    Atzori MG; Ceci C; Ruffini F; Trapani M; Barbaccia ML; Tentori L; D'Atri S; Lacal PM; Graziani G
    J Cell Mol Med; 2020 Jan; 24(1):465-475. PubMed ID: 31758648
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenib.
    Krayem M; Journe F; Wiedig M; Morandini R; Sales F; Awada A; Ghanem G
    Eur J Cancer; 2014 May; 50(7):1310-20. PubMed ID: 24559688
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Overexpression of the human antigen R suppresses the immediate paradoxical proliferation of melanoma cell subpopulations in response to suboptimal BRAF inhibition.
    Fernandez M; Sutterlüty-Fall H; Schwärzler C; Lemeille S; Boehncke WH; Merat R
    Cancer Med; 2017 Jul; 6(7):1652-1664. PubMed ID: 28573821
    [TBL] [Abstract][Full Text] [Related]  

  • 49. miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A.
    Caporali S; Amaro A; Levati L; Alvino E; Lacal PM; Mastroeni S; Ruffini F; Bonmassar L; Antonini Cappellini GC; Felli N; Carè A; Pfeffer U; D'Atri S
    J Exp Clin Cancer Res; 2019 Jun; 38(1):272. PubMed ID: 31227006
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6.
    Yoshida A; Lee EK; Diehl JA
    Cancer Res; 2016 May; 76(10):2990-3002. PubMed ID: 26988987
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An autophagy-driven pathway of ATP secretion supports the aggressive phenotype of BRAF
    Martin S; Dudek-Peric AM; Garg AD; Roose H; Demirsoy S; Van Eygen S; Mertens F; Vangheluwe P; Vankelecom H; Agostinis P
    Autophagy; 2017 Sep; 13(9):1512-1527. PubMed ID: 28722539
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.
    Martin CA; Cullinane C; Kirby L; Abuhammad S; Lelliott EJ; Waldeck K; Young RJ; Brajanovski N; Cameron DP; Walker R; Sanij E; Poortinga G; Hannan RD; Pearson RB; Hicks RJ; McArthur GA; Sheppard KE
    Int J Cancer; 2018 May; 142(10):2139-2152. PubMed ID: 29243224
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells.
    Vitiello M; Tuccoli A; D'Aurizio R; Sarti S; Giannecchini L; Lubrano S; Marranci A; Evangelista M; Peppicelli S; Ippolito C; Barravecchia I; Guzzolino E; Montagnani V; Gowen M; Mercoledi E; Mercatanti A; Comelli L; Gurrieri S; Wu LW; Ope O; Flaherty K; Boland GM; Hammond MR; Kwong L; Chiariello M; Stecca B; Zhang G; Salvetti A; Angeloni D; Pitto L; Calorini L; Chiorino G; Pellegrini M; Herlyn M; Osman I; Poliseno L
    Oncotarget; 2017 Apr; 8(15):25395-25417. PubMed ID: 28445987
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib.
    Sinnberg T; Makino E; Krueger MA; Velic A; Macek B; Rothbauer U; Groll N; Pötz O; Czemmel S; Niessner H; Meier F; Ikenberg K; Garbe C; Schittek B
    EBioMedicine; 2016 Jun; 8():132-149. PubMed ID: 27428425
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Melanoma cells with acquired resistance to vemurafenib have decreased autophagic flux and display enhanced ability to transfer resistance.
    Pérez CN; Falcón CR; Mons JD; Orlandi FC; Sangiacomo M; Fernandez-Muñoz JM; Guerrero M; Benito PG; Colombo MI; Zoppino FCM; Alvarez SE
    Biochim Biophys Acta Mol Basis Dis; 2023 Oct; 1869(7):166801. PubMed ID: 37419396
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-Term Vemurafenib Exposure Induced Alterations of Cell Phenotypes in Melanoma: Increased Cell Migration and Its Association with EGFR Expression.
    Molnár E; Garay T; Donia M; Baranyi M; Rittler D; Berger W; Tímár J; Grusch M; Hegedűs B
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31514305
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma.
    Qin Y; Roszik J; Chattopadhyay C; Hashimoto Y; Liu C; Cooper ZA; Wargo JA; Hwu P; Ekmekcioglu S; Grimm EA
    Mol Cancer Ther; 2016 Oct; 15(10):2442-2454. PubMed ID: 27458138
    [TBL] [Abstract][Full Text] [Related]  

  • 58. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
    Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
    [TBL] [Abstract][Full Text] [Related]  

  • 59. miR-224-5p acts as a tumour suppressor and reverses the resistance to BRAF inhibitor in melanoma through directly targeting PAK4 to block the MAPK pathway.
    Liu Y; Ruan H; Lu F; Peng H; Luan W
    Pathol Res Pract; 2023 Sep; 249():154772. PubMed ID: 37611431
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Upregulation of S100A9 contributes to the acquired resistance to BRAF inhibitors.
    Hwang SH; Ahn JH; Lee M
    Genes Genomics; 2019 Nov; 41(11):1273-1280. PubMed ID: 31388978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.